9 completed, 5 terminated, 4 recruiting, 4 unknown. 15 Phase 2, 10 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 5, Terminated 5, Unknown 3, Recruiting 1, Withdrawn 1 |
| Phase 1 | 10 | Completed 5, Unknown 3, Recruiting 2 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Oncotherapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone Selinexor, Ruxolitinib, Methylprednisolone - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 1 | Recruiting | Oncotherapeutics | 30 | 2024-08-06 | 2025-01-16 |
| A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Venetoclax - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | Recruiting | Oncotherapeutics | 39 | 2024-06-20 | 2025-01-16 |
| Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone - Multiple Myeloma | Early Phase 1 | Recruiting | Oncotherapeutics | 30 | 2022-12-08 | 2024-12-17 |
| Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. Selinexor, Lenalidomide, Methylprednisolone - Refractory Multiple Myeloma | Phase 1 | Unknown | Oncotherapeutics | 22 | 2020-11-01 | 2023-10-31 |
| Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients Ixazomib, Lenalidomide - Newly Diagnosed Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 19 | 2019-03-01 | 2023-10-25 |
| Combination Study for High Risk Multiple Myeloma Patients Elotuzumab, Pomalidomide, Carfilzomib - Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 13 | 2017-03-13 | 2022-03-31 |
| A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone - Multiple Myeloma | Phase 1 | Recruiting | Oncotherapeutics | 134 | 2017-02-01 | 2023-11-01 |
| Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib Carfilzomib, Dexamethasone, Prednisone - Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 45 | 2014-12-01 | 2023-11-01 |
| Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors PEG-BCT-100 - Melanoma, Prostate Adenocarcinoma | Phase 1 | Completed | Bio-Cancer Treatment International Limited | 23 | 2014-11-01 | 2020-04-24 |
| Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients Melphalan, Prednisone, Cyclophosphamide - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Oncotherapeutics | 45 | 2014-09-01 | 2023-10-31 |
| Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients POM, Steroids, PLD - Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 45 | 2014-07-07 | 2023-11-03 |
| Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma Carfilzomib and Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Oncotherapeutics | 38 | 2013-04-01 | 2018-03-05 |
| Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients Multiple Myeloma, Peripheral Neuropathy | Completed | Oncotherapeutics | 110 | 2012-06-01 | 2018-03-05 | |
| Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens Subcutaneous bortezomib - Multiple Myeloma | Phase 2 | Terminated | Oncotherapeutics | 5 | 2012-05-01 | 2017-01-16 |
| Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma Pomalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Oncotherapeutics | 70 | 2012-02-01 | 2016-03-10 |
| Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen. - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Oncotherapeutics | 39 | 2011-05-02 | 2018-03-05 |
| A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma armodafinil, Placebo - Fatigue, Multiple Myeloma | Phase 3 | Completed | Oncotherapeutics | 50 | 2010-06-01 | 2014-11-06 |
| Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma DVD-R - Multiple Myeloma | Phase 2 | Completed | Oncotherapeutics | 40 | 2009-09-01 | 2015-05-04 |
| Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride - Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Unknown | Oncotherapeutics | 35 | 2008-07-01 | 2013-12-18 |
| Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma Melphalan, Panobinostat - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Oncotherapeutics | 40 | 2008-07-01 | 2014-05-08 |
Showing 20 of 23. Sign in to see all of them.
Multiple Myeloma (22) · Recurrence (5) · Neoplasms, Plasma Cell (4) · Fatigue (1) · Melanoma (1) · Neoplasms (1) · Peripheral Nervous System Diseases (1)
Dexamethasone (7) · Lenalidomide (7) · Bortezomib (6) · Methylprednisolone (5) · pomalidomide (5) · Calcium Dobesilate (4) · Melphalan (4) · carfilzomib (4) · Ascorbic Acid (3) · Methylprednisolone Acetate (3) · Prednisone (3) · liposomal doxorubicin (3) · ruxolitinib (3) · 1-dodecylpyridoxal (2) · Cyclophosphamide (2)
United States (23)
James R Berenson, MD (9) · James R. Berenson, MD (6) · James Berenson, MD (4) · Alberto Bessudo, MD (1) · James Berenson, M.D. (1) · James R. Berenson, M.D. (1) · Joshua Richter, M.D (1) · Steven O'Day, MD (1)
PMID 19188182, PMID 19226361, PMID 22354206, PMID 24135804, PMID 24429497, PMID 29776373, PMID 31937615, PMID 34818965, PMID 35946431, PMID 36482815, PMID 38643346